PL2061444T3 - Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii - Google Patents

Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii

Info

Publication number
PL2061444T3
PL2061444T3 PL07841298T PL07841298T PL2061444T3 PL 2061444 T3 PL2061444 T3 PL 2061444T3 PL 07841298 T PL07841298 T PL 07841298T PL 07841298 T PL07841298 T PL 07841298T PL 2061444 T3 PL2061444 T3 PL 2061444T3
Authority
PL
Poland
Prior art keywords
ameliorating
treating
reducing
controlling
compositions
Prior art date
Application number
PL07841298T
Other languages
English (en)
Inventor
Brian R Rohrs
Timothy L Comstock
Zhenze Hu
Gary Phillips
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of PL2061444T3 publication Critical patent/PL2061444T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07841298T 2006-09-11 2007-08-24 Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii PL2061444T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84362906P 2006-09-11 2006-09-11
EP07841298A EP2061444B1 (en) 2006-09-11 2007-08-24 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
PCT/US2007/076701 WO2008033655A2 (en) 2006-09-11 2007-08-24 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy

Publications (1)

Publication Number Publication Date
PL2061444T3 true PL2061444T3 (pl) 2011-09-30

Family

ID=38819731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07841298T PL2061444T3 (pl) 2006-09-11 2007-08-24 Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii

Country Status (17)

Country Link
US (1) US20080064721A1 (pl)
EP (1) EP2061444B1 (pl)
JP (1) JP2010502723A (pl)
KR (1) KR20090050076A (pl)
CN (1) CN101553214B (pl)
AT (1) ATE506061T1 (pl)
AU (1) AU2007297054A1 (pl)
BR (1) BRPI0716625A2 (pl)
CA (1) CA2661197C (pl)
DE (1) DE602007014067D1 (pl)
DK (1) DK2061444T3 (pl)
ES (1) ES2361585T3 (pl)
MX (1) MX2009002544A (pl)
PL (1) PL2061444T3 (pl)
PT (1) PT2061444E (pl)
TW (1) TWI344467B (pl)
WO (1) WO2008033655A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
WO2013126156A1 (en) * 2012-02-22 2013-08-29 Bausch & Lomb Incorporated Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions
CA3123490A1 (en) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing
WO2026015094A1 (en) * 2024-07-06 2026-01-15 Humanis Sağlik A.Ş. Syrup compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
WO1995019181A1 (en) * 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
MXPA02005007A (es) * 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2003202216A1 (en) * 2002-01-14 2003-07-30 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
CA2478156C (en) * 2002-03-26 2011-02-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082787A1 (en) * 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4503436B2 (ja) * 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
CA2512257A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP1730145A1 (en) * 2004-03-22 2006-12-13 Boehringer Ingelheim Pharmaceuticals Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
JP2008535884A (ja) * 2005-04-14 2008-09-04 グラクソ グループ リミテッド グルココルチコイド受容体リガンドとしてのインダゾール

Also Published As

Publication number Publication date
JP2010502723A (ja) 2010-01-28
WO2008033655A3 (en) 2008-10-02
PT2061444E (pt) 2011-07-08
EP2061444B1 (en) 2011-04-20
ES2361585T3 (es) 2011-06-20
CN101553214B (zh) 2012-12-26
CA2661197C (en) 2012-01-03
AU2007297054A1 (en) 2008-03-20
DK2061444T3 (da) 2011-06-27
CN101553214A (zh) 2009-10-07
TW200819442A (en) 2008-05-01
BRPI0716625A2 (pt) 2013-10-08
US20080064721A1 (en) 2008-03-13
CA2661197A1 (en) 2008-03-20
ATE506061T1 (de) 2011-05-15
MX2009002544A (es) 2009-03-20
DE602007014067D1 (de) 2011-06-01
KR20090050076A (ko) 2009-05-19
TWI344467B (en) 2011-07-01
WO2008033655A2 (en) 2008-03-20
EP2061444A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
PT2061444E (pt) Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
TW200626558A (en) Indazolone derivatives
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
WO2007101005A3 (en) Compositions and methods for effecting controlled posterior vitreous detachment
WO2007126964A3 (en) Kinase inhibitors
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
MY157790A (en) Trazodone composition for once a day administration
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
DK2051710T3 (da) Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment
WO2004010936A3 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
PT2190431E (pt) Composições compreendendo um agonista do recetor dos glucocorticoides dissociados para tratamento ou controlo de inflamação do segmento anterior
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
WO2007016147A3 (en) Topical skin protectant and anti-pruritic compositions
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
EP4143205A4 (en) COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES
TW200732304A (en) Piperidine derivatives
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.